Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
2.
Invest Ophthalmol Vis Sci ; 52(12): 9033-46, 2011 Nov 21.
Article in English | MEDLINE | ID: mdl-21969301

ABSTRACT

PURPOSE: Immunization with glatiramer acetate (GA) alleviates the neuropathology associated with glaucoma and Alzheimer's disease (AD) in rodent models. This research was undertaken to screen for molecular factors underlying GA-induced neuroprotective mechanisms in these models of chronic neurodegeneration. METHODS: Gene expression profiles were analyzed in GA-immunized versus nonimmunized elevated-intraocular pressure (IOP) rat models of glaucoma by using whole genome cDNA microarrays and were further validated by quantitative real-time PCR analysis. A gene, prominently upregulated by GA in elevated IOP retina, was further studied in APP(SWE)/PS1(ΔE9)-transgenic (AD-Tg) mice after GA immunization. RESULTS: Seven days after treatment with GA, numerous genes were regulated in the retinas of rats with elevated IOP. Comprehensive functional classification and DAVID/KEGG enrichment analysis of GA-induced differentially expressed genes revealed annotation terms and pathways involved in neuroprotection, immune responses, cell communication, and regeneration. Specifically, increased mRNA levels of an early growth response (Egr) 1 gene were evident in GA-immunized retinas with elevated IOP. In AD-Tg mice, a significant increase in hippocampal EGR1 protein levels was also found in response to GA immunization. Nuclear EGR1 in the dentate gyrus colocalized more frequently with doublecortin-positive and Ki67 proliferating neural progenitors in GA-immunized as compared to nonimmunized AD-Tg mice. Further, EGR1 levels were negatively correlated with hippocampal amyloid-ß plaque burden. CONCLUSIONS: This study presents global gene expression profiles associated with GA immunization in a glaucoma rat model. Moreover, it identifies EGR1 transcription factor as a potential mediator for GA-induced neuroprotection in both glaucoma and AD.


Subject(s)
Alzheimer Disease/drug therapy , Early Growth Response Protein 1/genetics , Glaucoma/drug therapy , Immunosuppressive Agents/pharmacology , Peptides/pharmacology , Alzheimer Disease/genetics , Alzheimer Disease/immunology , Animals , Chronic Disease , Disease Models, Animal , Doublecortin Protein , Female , Gene Expression/drug effects , Gene Expression/immunology , Glatiramer Acetate , Glaucoma/genetics , Glaucoma/immunology , Hippocampus/physiology , Male , Mice , Mice, Transgenic , Nerve Degeneration/drug therapy , Nerve Degeneration/genetics , Nerve Degeneration/immunology , Neuroprotective Agents/pharmacology , Oligonucleotide Array Sequence Analysis , Rats , Rats, Inbred Lew , Real-Time Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...